Hemostemix Inc. specializes in autologous stem cell therapeutics, focusing on the derivation of three distinct stem cell lineages from a patient's own blood. The company holds 91 patents related to these technologies, which include angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 has been clinically tested in over 500 subjects and has shown safety and efficacy in treating conditions such as Angina, Dilated and Ischemic Cardiomyopathy, Peripheral Arterial Disease, and Critical Limb Ischemia. The process involves extracting blood from the patient, differentiating it into ACP-01 cells, and reintroducing these cells into the heart to promote new blood vessel formation and regeneration in areas where circulation is compromised.

In addition to its core technology, Hemostemix has developed a patented automated cell therapy system (ACTS Production) aimed at scaling production to meet increasing demand. The company is currently focused on expanding its clinical trials and production capabilities, with plans to produce up to 4,000 batches of ACP-01 per month by the end of 2027. This innovative approach not only enhances the therapeutic options available for patients with severe cardiovascular conditions but also positions Hemostemix as a leader in the field of regenerative medicine. The company’s commitment to advancing its technologies is further exemplified by its partnerships and ongoing clinical studies, which aim to provide effective treatments for patients with limited options.

Canada

Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions that are not adequately addressed by current treatments.

Hemostemix

Company Details